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Abstract 
Bladder cancer (BC) is a heterogeneous disease characterized by a high recurrence rate 
that necessitates continuous cystoscopic surveillance. 
microRNAs (miRNAs) are detectable in tissues and biofluids such as plasma/serum and 
urine). They represent promising biomarkers with potential not only for detecting BC but 
also informing on prognosis and monitoring treatment response. 
In this review, the many aspects of the application of next generation sequencing (NGS) to 
evaluate miRNA expression in BC is discussed including technical issues as well as a 
comparison with results obtained by qRT-PCR. The available studies investigating miRNA 
profiling in BC by NGS are described, with particular attention to the potential applicability 
on biofluids. 
Altered miRNA levels have been observed in BC tissues by NGS, but these results so far 
only partially overlapped among studies and with previous data obtained by qRT-PCR. 
The discrepancies can be ascribed to the small groups of BC patients sequenced. The few 
available studies on biofluids are mainly focused on implementing RNA isolation and 
sequencing workflow. Using NGS to analyze miRNAs in biofluids can potentially provide 
results comparable to tissues with no invasive procedures for the patients. In particular, 
the analyses performed on exosomes/microvesicles seem to be more informative.  
Thanks to the improvement of both wet-lab procedures and pipelines/tools for data 
analyses, NGS studies on biofluids will be performed on a larger scale. miRNAs detected 
in urine and serum/plasma will demonstrate their potentiality to describe the variegated 
scenario of BC and to become relevant clinical markers. 
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1. Bladder cancer 
Bladder cancer (BC) is one of the leading causes of cancer-related death worldwide, with 
an estimated 429,000 new cases in 20121. The risk of BC rises with age, peaking between 
the ages 50-70, and is three times more common in men than in women2. Besides age 
and gender, other risk factors are genetic and molecular abnormalities, chemical or 
environmental exposures, and chronic irritation. Tobacco use, occupational exposures to 
aromatic amines and polycyclic aromatic hydrocarbons, as well as Schistosoma 
haematobium infections and exposure to ionizing radiation are among BC environmental 
risk factors3-5. Several oncogenes (TP636, EGFR7, and PIK3CA5) and tumour suppressor 
genes (TP53, RB18, and PTEN4) also play a role in the genetic pathogenesis of BC 
(Supplementary Table 1). Polymorphisms in NAT2 and GSTM1 genes and other single-
nucleotide polymorphisms (SNPs) in candidate genes (MYC; TP63; PSCA; TERT; 
CLPTM1L; FGFR3; TACC3; NAT2; CBX6; APOBEC3A; CCNE1 and UGT1A) have been 
associated with increased risk of BC, particularly in relation to smoking9. Recently, other 
potential markers for BC risk estimation, prognosis and response to therapy have been 
identified (SNPs in DNA repair genes10-12 or leukocyte telomere length13). However, no 
molecular markers have been included yet in the clinical practice mainly because of the 
divergent results among studies. Only few examples, like p53, pRb, p21 and survivin, have 
proved to have a predictive value in studies with a large and homogeneous patient 
population undergoing standardized treatment4. 
 
BC is a heterogeneous disease. Two main subsets are identifiable: non-muscle-invasive 
BC (NMIBC), confined to mucosa or submucosa and with superficial, non-infiltrating 
lesions, and muscle invasive BC (MIBC)4. About 70% of BC patients are diagnosed 
NMIBC, but as many as 50–70% of them will recur, and roughly 10–20% will progress to 
MIBC14. MIBCs are the major contributors to BC-related mortality. Since MIBC and NMIBC 
are highly distinct, a “two-pathway” model, taking into account both histopathological and 
molecular features, has been proposed. In this model, NMIBC develops via epithelial 
hyperplasia and recruitment of a branching vasculature while MIBC is derived from flat 
dysplasia and carcinoma in situ (CIS)5. Nevertheless, there is still considerable 
heterogeneity in clinical behaviour that cannot be explained by a single model. A tentative 
implementation of the model with a molecular characterization of BC subtypes has been 
recently published5. The development of multiple BCs in the same individual is quite 
common, generating the hypothesis of multiple foci and molecular evolution of the tumour. 
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After extensive carcinogenic insults, many altered cells can give rise to independent 
tumours. As an alternative, a single clone may spread via intraepithelial implantation. In 
patients with multiple BCs, malignancies are often related because of a subclonal genomic 
evolution15. Therefore, intratumoral heterogeneity should be taken into consideration. 
Recent analyses using high-throughput, massive parallel sequencing technology (next 
generation sequencing, NGS) should allow such complexity and phylogeny to be 
unravelled5. 
Cancer screening and early diagnoses have primary importance in improving survival of 
patients. Currently, urine cytology is most commonly used as a non-invasive test for the 
detection of BC. However, this test is of limited value owing to its poor sensitivity, 
especially for low-grade lesions16-18. Cystoscopy-guided biopsy for histological evaluation 
can offer high diagnostic accuracy, but it is invasive and inconvenient for patients, which 
limits its use for general cancer screening. BC is among the most expensive cancers and 
poses a significant economic challenge because the high rate of recurrence necessitates 
continuous cystoscopic surveillance19. Hence, non-invasive and more sensitive molecular 
biomarkers are needed to improve current strategies for the detection and monitoring of 
BC.  
2. MicroRNAs and bladder cancer. 
RNA expression levels are highly dynamic and are affected by several different stimuli, 
providing a valuable source of biomarkers. Nearly 98% of human RNA is not translated 
into proteins and constitutes the so-called non-coding RNA (ncRNA). Small ncRNAs 
(microRNAs (miRNAs), small nucleolar RNAs, transfer RNAs, endogenous small 
interfering RNAs and PiWi-interacting RNAs), initially discarded as RNA turnover artefacts; 
are now revealing their functional activities20. In particular, miRNAs (~22 nucleotides in 
length) constitutes an attractive biomarker source for cancer research21. miRNAs post-
transcriptionally regulate gene expression mainly by binding to the 3' untranslated region 
(UTR) of target messenger RNAs (mRNAs)22. They also have a very broad set of other 
targets that include 5`UTRs23, intronic and intergenic transcripts24, pseudogenes25, short 
interspersed elements26, and circular RNAs27. 
miRNAs are involved in several cellular processes and in the majority of known hallmarks 
of cancer, including initiation, development and metastasis28, 29. A growing body of 
evidence indicates that many human cancers show aberrant miRNAs acting as tumour 
suppressors or oncogenes30. From a biological standpoint, miRNAs may be more 
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informative predictive and prognostic markers than protein, mRNA, or DNA. A single 
miRNA may regulate up to hundreds of target mRNAs frequently grouped in specific 
biological pathways. Altered miRNA levels may lead to dysregulated dosage of their target 
genes, which often dictates aberrant functional readouts of multiple molecular pathways 
during carcinogenesis31. Finding the differentially expressed miRNAs (DEmiRNAs) in 
various cancers may help in understanding the miRNA-mediated oncogenic pathways and, 
subsequently, give direction in the treatment32. Currently, miRNA signatures are being 
applied in clinical trials, and miRNA-directed therapy is on the road to clinical 
implementation33. From a practical viewpoint, miRNAs are more stable than mRNAs or 
proteins and less subject to degradation during sample processing. Thus, they are more 
suitable for analysis in formalin-fixed paraffin-embedded (FFPE) tissues, urine, serum, or 
plasma29, 34, 35. 
Array- and PCR-based technologies have enabled so far the analysis of a large but not 
exhaustive number of miRNAs. Until recently, microarrays have represented the more 
cost-effective and reliable approach allowing the analysis, in a single experiment, of large 
gene/miRNA expression patterns. However, hybridization-based platforms suffer from 
background and cross-hybridization issues, and the limited dynamic range makes it 
difficult to detect and quantify with confidence low- and high-abundance transcripts36, 37. 
Moreover, a priori knowledge of sequences to interrogate still represents a limitation. In 
miRBase, 2588 human mature miRNAs are registered 
(http://www.mirbase.org/index.shtml, Release 21-June 2014), but the number is constantly 
increasing, and the available platforms cannot keep pace with the increasing number of 
newly discovered species38. 
A huge number of studies have investigated miRNA expression in BC by quantitative real-
time PCR (qRT-PCR) either on FFPE or frozen tissues. Several miRNAs (miR-20539, 40, 
miR-141, miR-125b42, miR-14343-45, miR-22139, and miR10146) have repeatedly been found 
dysregulated in BC tissues but usually in relatively small studies (maximum 100 samples, 
but on average 50, see34, 47-49). A signature of 11 DEmiRNAs (miR-1, miR-26a, miR-29a,c, 
miR-100, miR-133a,b, miR-125b, miR-143-3p, miR-145-5p, and miR-195) has been 
recently proposed34 (Table 1). 
The advent of NGS should allow a more comprehensive miRNA analysis, including the 
detection of new miRNAs with a tissue-specific expression, giving more information on BC 
genomics38, 50-55. 
6 
 
3. microRNA expression in bladder cancer tissues: new insights from Next 
Generation Sequencing (NGS)  
Six studies investigated miRNA signatures in BC by NGS so far, almost exclusively on 
primary tissues (Table 2). The first study on 9 tumour tissues and 9 normal bladder 
epithelium from the same patients was performed in 2011 by Han and colleagues56. The 
authors found 656 DEmiRNAs, with some specific clusters (miR-183, miR-200b~429, miR-
200c~141 and miR-17~92) up-regulated and the miR-143~145 cluster down-regulated. 
Many details regarding their NGS methodology, such as the number of detected/mapped 
reads, were missing. The validation of these results by qRT-PCR (in the same patients 
and an additional 42 BC pairs) was unclear. Of the large number of significantly 
DEmiRNAs, the authors validated only some miRNAs of each cluster, but not necessarily 
those found most significantly deregulated. Moreover, in the validation step no reference 
genes nor any other normalization strategy were reported. This study56 was followed up by 
integrating some of the DEmiRNA results by NGS with DNA methylation and expression 
profiles of both mRNAs and miRNAs57. Five hundred forty-three miRNAs were expressed 
in at least one of the samples (either tumour or normal tissues) with 196 of them altered 
(156 up- and 40 down-regulated). For instance, among the up-regulated were miR-182, 
miR-183, miR-10a, miR-203, and miR-224 while miR-133a, miR-133b, and miR-125b were 
among the down-regulated57.  
An additional follow-up study including the patient data described above56 analysed 
mRNA/miRNA expression profiles generated by NGS analysis of three different 
genitourinary cancers: carcinomas of the bladder, kidney and testis58. In particular, 226 
DEmiRNAs were detected in BC (182 up- and 44 down-regulated). Of these, 104 and 20 
respectively up- and down-regulated miRNAs were unique to BC while the rest were in 
common with the other genitourinary cancers analysed. Overall, 9 up- and 8 down-
regulated DEmiRNAs displayed consistent patterns in all three of the cancers58.  
Chen and colleagues reported 74 DEmiRNAs, 33 up- and 41 down-regulated, in BC when 
compared with normal bladder epithelium59. Among the most interesting were the let-7 
family miRNAs , miR-1268, miR-196a, miR-1, miR-100, miR-101, and miR-143, with miR-1 
showing about 8-fold decreased expression levels in the BC library in comparison with the 
one from normal epithelia59. 
It is relevant to say that DEmiRNAs detected in this initial set of studies were consistent 
with previously published data and confirmed other findings obtained by qRT-PCR (Table 
1).  
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In a more recent study60, five BC and five matched histologically normal urothelial 
epithelium were sequenced. Out of 933 known miRNAs detected, 60, all down-regulated, 
DEmiRNAs were observed in cancer tissue. Interestingly, several of those miRNAs were 
known to be in clusters. In the validation step by qRT-PCR, the authors focused on the 
miR195~497 cluster since it contains known tumour suppressor miRNAs. Notably, 17 
potential new miRNAs were identified. However, the expression levels of these miRNAs 
were low, and their functional role was not further assessed. 
The largest NGS study so far on BC is a comprehensive investigation by The Cancer 
Genome Atlas (TCGA) Research Network61. Tissues from 131 high-grade MIBC patients 
were analysed by RNA sequencing together with 118 blood samples from the same 
individuals and 23 tumour-adjacent, histologically confirmed, normal-appearing tissues. 
The aim of the project was the genetic and epigenetic characterization of the molecular 
landscape of high-grade MIBC. Even though the results presented can have a huge 
impact on oncological research, miRNA sequencing data were reported more as a 
refinement of clusters generated by preliminary analyses of somatic mutations, exome 
sequencing and mRNA expression rather than as specific cancer biomarkers. 
Interestingly, the tumours that were classified in clusters defined by a number of molecular 
characteristics showed not only an increased number of mutations, copy number gain and 
elevated expression of the FGFR3 gene, but also a lower expression of miR-99a and miR-
100, which have this gene among their targets. In addition, in the same cluster, miR-145 
and miR-125b were found down-regulated as previously observed in BC34.  
The studies, hereby reported, focused mainly on different miRNA profiles among cancer 
tissues and normal adjacent epithelia without any regard to the different tumour types and 
not considering the quite heterogeneous nature of the bladder tumour. The only exception 
is represented by the TCGA project61, which was specifically focused on high-grade MIBC. 
miRNA signatures obtained from these preliminary studies are partially comparable among 
themselves and with previous data obtained by qRT-PCR (Table 1). Although NGS and 
qRT-PCR profiles are not comparable from the quantitative point of view, the sequencing 
approach should bring a significant improvement in transcriptome analyses. 
4. microRNAs in body fluids as biomarkers for bladder cancer  
There is a pressing need for highly accurate, non-invasive tests to assist BC diagnosis and 
surveillance. The standard procedures for BC diagnosis and the follow-up of patients are 
urinary cytology and cystoscopy. The first demonstrates a rather low diagnostic sensitivity 
for low-grade tumours while cystoscopy is an expensive and invasive test. A number of 
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non-invasive urine tests have been developed so far (based on antibodies immunoassay 
detecting proteins in urine62, 63) but their diagnostic sensitivity and specificity have failed to 
live up to the clinical expectations28. In this respect, assessing if quantitative/qualitative 
changes in miRNAs in tumour tissues are also mirrored in urine and plasma is of primary 
importance in the search for new markers. miRNAs are detectable as cell-free molecular 
components in biofluids, both in cancer patients and healthy controls. In BC, nucleic acids 
released from malignant cells are typically found in serum/plasma or urine as extracellular 
molecules. Conversely, cancer cells detached from the tumour could occur in the cellular 
compartment of urine, in addition to blood cells or normal urinary tract cells63-66 (Figure 1). 
miRNAs in biofluids are classified as extracellular, circulatory or cell-free miRNAs and they 
occur in extracellular vesicles (exosomes (40–100nm), shedding vesicles (0.1–1µm) and 
apoptotic bodies (1–4μm)) or in association with high-density lipoprotein particles or Ago2 
proteins. The mechanism of miRNAs transportation to circulation is still largely unknown, 
as well as their functions in biofluids64. Recently it has been hypothesized that miRNAs in 
extracellular vesicles may influence adjacent cells and could determine the specific 
microenvironment and also may exert miRNA-based signal transduction between cells in 
body fluids67. Significant changes in the circulatory miRNAs expression have been 
reported for many cancers, suggesting extracellular miRNAs as potential non-invasive 
biomarkers for cancer diagnosis and prognosis68-71. Moreover, there is a correspondence 
between the DEmiRNAs in the specific cancer tissue and in blood and other biofluids72. 
Changes in body fluids reflect ‘‘disturbed homeostasis’’ and constitute the rationale for 
their potential use as biomarkers for prevention, diagnosis, prognosis and follow-up of 
human diseases (Figure 1). 
Several databases permit a rapid search of the studies investigating DEmiRNAs in 
biofluids (ExcellmiRDB73; Exocarta74; miRandola75). However, the reported studies are 
based on qRT-PCR with a candidate miRNA approach (reviewed in63). Despite highly 
significant results for expression changes of extracellular miRNAs in cancer diseases, 
observations from single studies do not overlap and sometimes even contrast. 
4.1 Plasma/serum 
For the determination of miRNA markers in serum/plasma samples, several important pre-
analytical variables must be considered such as blood sampling, handling and processing 
procedures. Results on miRNA concentrations in plasma and serum are still contradictory, 
and this issue seems to be partly dependent on the miRNA analysed70, 76. 
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Plasma is the cell-free supernatant obtained by centrifuging blood that has been collected 
in the presence of an anticoagulant. Serum is obtained after centrifuging blood that has 
been allowed to clot spontaneously in the absence of an anticoagulant77. A number of 
aspects need to be considered when working with these specimens. Haemolysis, for 
example, may affect the variability of miRNAs and relative quantity in plasma/serum. Some 
miRNAs are haemolysis-susceptible, such as miR-16, miR-17, miR-21, miR-92a, and miR-
106a; therefore, they should not be considered as biomarkers in blood-derived biofluids78. 
Additionally, the method used for miRNA extraction may influence the yield of material. 
RNA yielded from plasma/serum samples is generally below the analytical sensitivity of the 
quantification method, or its amount is insufficient for both quantification and qRT-PCR 
measurements. Thus equal volumes of unknown quantities of the isolated RNA are used 
for the qRT-PCR measurements79. Guidelines have been published to control and, in 
certain ways, to compensate for the variations in the different steps of the quantification 
method, and a standard normalization procedure has been recommended80, 81. 
The application of NGS to measure miRNAs in serum/plasma is still in its early phase. 
However, short RNA sequencing of 1323 samples of 13 distinct human tissue types, 
including serum, has revealed some of its potentiality. Novel identified miRNAs displayed 
species- and tissue-specific patterns of expression55. 
All the studies investigating DEmiRNAs in serum/plasma of BC patients were so far based 
on a small number of subjects, using a candidate miRNA approach, and with a non-
precise characterization of the cancer63, 82(Table 1). The first comprehensive plasma 
miRNA profiling for BC detection was done by using a custom-made ncRNA array83. Out of 
all miRNAs analysed in 10 NMIBC, 10 MIBC, and 18 controls, authors could identify at 
least 10 plasma DEmiRNAs in cases and controls. Although some limitations were 
evident, this work supports the feasibility and efficacy of this approach. 
Only one study84 performed miRNA profiling on serum with an NGS approach to find 
biomarkers of BC diagnosis and recurrence (Table 3). Pools of 10 NMIBCs, 10 MIBCs and 
10 healthy controls were sequenced. Among the 529 miRNAs mapped, 180, 259 and 206 
miRNAs were detected (>10 copies) in controls, NMIBC and MIBC patients, respectively. 
Considering 50 copies as a minimum detection level, and a 2-fold change in expression 
levels as thresholds, 26 DEmiRNAs were found in BC (8 up- and 18 down-regulated). 
Further training (120 BC patients and 120 controls) and validation (110 BC patients and 
110 controls) phases highlighted six DEmiRNAs (miR-152, and miR-148b-3p up-regulated; 
miR-3187-3p, miR-15b-5p, miR-27a-3p, and miR-30a-5p down-regulated). The reported 
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panel had a higher sensitivity to detect patients with early stage diseases (Ta and T1) 
compared to traditional urine cytology, giving enough confidence that the 6-miRNAs 
expression profiles could serve as an accurate biomarker for BC detection. In addition, 
miR-152 was identified as an independent factor for tumour recurrence in NMIBC 
patients84. 
Notably, present NGS analyses may suffer from the limitation that the results were from 
pooled serum samples. Pooling RNA samples helps to defray the experiments' cost as well 
as to correct for the technical difficulties in getting sufficient amounts of RNA from all 
subjects analysed. However, this approach does not provide an estimate of variability 
among individuals and batches85. A good validation strategy is always recommended but 
in one report84 the number of cases representing each tumour type (for example by T 
classification) was low. Considering the high heterogeneous nature of BC, to fully 
understand and clarify the value of miRNAs as biomarkers in serum/plasma, more and 
larger studies are warranted. 
The matter is further complicated by the fact that in blood, miRNAs are either associated 
with proteins, such as Ago2, lipoproteins or contained within cellular fragments (exosomes, 
microparticles, or extracellular vesicles). Extraction and analysis of miRNAs from any or all 
of these components may pose specific challenges and yield different results86. A recent 
study provided guidelines for blood-based exosomal RNA sequencing analyses that, if 
properly followed, could contribute to a better assessment of experiments87. 
4.2 Urine 
BC cells are in direct contact with urine making this biofluid an ideal source for the 
detection of cancer biomarkers. Urine is collected non-invasively, and the procedure is 
relatively fast and cost-efficient compared with other clinical samples. In addition, sampling 
can be repeated at different times, and this makes urine an attractive candidate as a 
clinical test for a cancer like BC that needs constant monitoring. However, the 
measurement of urine biomarkers is also affected by the same pre-analytical and 
analytical issues previously raised for plasma/serum. Urine collection (including 
preservatives used in the collection tubes, time of the day for sampling, etc.) as well as the 
choice to use whole, native urine or sediments/supernatants (after centrifugation step) may 
affect sample collection. In addition, isolation procedures and quantification may also 
weigh on miRNA detection and qualitative assessment. There is still ambiguity regarding 
which type of specimen should be considered among whole urine, sediments, supernatant 
or exosomes. The majority of urinary miRNAs originates from renal and urethral cells, and 
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analysis of these cells can provide a measure of the health of the excretory system88. 
Similarly to those circulating in plasma/serum, extracellular miRNAs from other tissues can 
be delivered to renal epithelial cells and released into the urine bound to RNA-binding 
proteins89 or packaged into exosomes90(Figure 1). 
The first study on urinary DEmiRNAs in BC was done on 83 patients by qRT-PCR91. A 
number of studies with a similar approach followed (reviewed by63; Table 1). The few 
studies conducted were based on a candidate-driven approach and so far have shown 
mixed results about the utility of miRNAs as urinary biomarkers of BC. The low specificity 
of several studies may be due to heterogeneous case and control groups, as well as the 
use of controls with haematuria and other benign urologic conditions92, 93. 
No studies were done so far to profile urinary miRNAs in BC using NGS. Recently, 
exosomal and non-exosomal miRNAs have been systematically characterized in human 
urine from healthy donors94 (Table 3). The authors tested various methodologies to obtain 
high exosomal yields from minimal urine volumes and compared different commercially 
available RNA extraction kits for urine and urinary exosomes in order to maximize RNA 
yields. NGS was used to profile baseline miRNAs and other small ncRNAs in exosomes, in 
cell pellet, and in cell-free urine. Finally, they identified 66-184 miRNAs in exosomes 
according to the extraction method used, with the majority in common among the healthy 
urine sample donors. Only 12 miRNAs were abundantly expressed in cell-free urine, 
although the initial RNA yield measured was high. Two miRNAs, miR-3648 and miR-4516, 
were specifically detected in cell-free urine94. Massive parallel sequencing was performed 
by Ion-Torrent, for which there are still not enough studies to compare results. The 
methodology is in need of some refinements and improvements; for example, the analyses 
were done starting from 3 pooled urine samples and in relatively high RNA amounts. As 
the use of NGS increases, this method seems suitable for analysing circulating miRNA 
profiles in urine for biomarker discovery applications in urothelial carcinoma. 
5. Future perspectives 
A deep characterization of the genomic landscape of BC is still lacking95. The majority of 
studies on miRNAs have focused so far on candidate gene approaches, with limited 
whole-genome sequencing. The few published NGS studies have focused predominantly 
on BC tissues, without any particular selection according to the clinical and demographic 
characteristics. Only recently, specific BC subcategories were investigated12, 61. This is 
probably the main reason for lack of reproducibility among the majority of the studies since 
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MIBC and NMIBC have highly distinct molecular characteristics5. This aspect is relevant 
also for the research on biofluids, where the NGS approach is still in its infancy.  
Recently, a comparison of the available miRNA profiling technologies has been 
performed96. Each analysed technique/platform presented their own strengths and 
weaknesses. Overall, when compared with the gold-standard qRT-PCR, NGS 
demonstrated the greatest detection sensitivity, the largest dynamic range of detection and 
the highest accuracy in differential expression analysis59, 97. NGS also represents a unique 
tool to investigate different layers of transcriptome complexity at an incredible level of 
resolution96. In addition, NGS can discriminate miRNA isoforms, which is complicated for 
qRT-PCR probes/primers, and the analyses procedure can be repeated over time with the 
most updated mapping. On the other hand, NGS data are more qualitative than 
quantitative, since for samples from a single condition it is possible only to establish if a 
gene/miRNA is relatively expressed. The huge range of reads produced can, in fact, 
introduce problems such as false high fold changes resulting from very small expression 
values, or other errors due to de-multiplexing and alignment ambiguity. Furthermore, many 
approaches have been developed for sequencing data analyses, but there is no clear 
consensus on which generates the most reliable results. Some attempts to standardize all 
these negative aspects have been done98-101. 
In the majority of the miRNA NGS studies, samples were pooled together in the interest of 
increasing RNA yield and reducing the analyses to small groups to minimize costs. With 
the recent reductions in the cost of NGS, it is becoming more feasible to analyse larger 
amount of samples. 
Additional studies are also needed to define the best nucleic acids extraction methods and 
the procedure for the preparation of the small RNA libraries. In turn, NGS on small RNAs 
can potentially clarify the role of other less known ncRNAs in normal and malignant cells, 
which is a recently emerging field of research20, 102-104102-104.  
No validation/replication was performed in most of the available NGS studies on BC. This 
step is essential for all high-throughput technologies. In those few studies that did include 
replication, no clear and standard criteria were employed. 
Increasing the number of well-designed systematic studies to determine optimal 
preanalytical and analytical conditions is urgently needed to translate applicability to 
clinical practice. It is worthwhile to consider miRNAs both in urine/urinary exosomes and 
serum/plasma as potential BC biomarkers, and we expect interesting results to emerge in 
the near future. 
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Legend to figure 
Figure 1. Putative sources of circulating microRNAs (miRNA). miRNAs in circulation may 
originate from apoptotic or necrotic cells as well as cancer cells from advanced/metastatic 
bladder tumour. miRNAs may be released in blood vessels aggregated to protein 
complexes or via secretory vesicles such as exosomes or microvesicles. In addition, they 
can also be secreted in free form by some unknown mechanisms. Urinary miRNA 
originates from renal and urethral cells. As plasma/serum circulating extracellular miRNA 
from other tissues within the body can be delivered to renal epithelial cells and released 
into the urine. In non-invasive BC, tumour cells having a turnover release also miRNAs 
bound to RNA-binding proteins or packaged into microvesicles such as exosomes. 
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Table 1 Overview of DEmiRNAs in BC identified by qRT-PCR or NGS in tissues and biofluids  
Investigated 
specimen 
DEmiRNAs studied by qRT-PCR References in 
the review 
Original article DEmiRNAs studied by NGS References in the 
review 
Cancer 
tissue 
miR-129, miR-133b, miR-145, miR-518c*, 
miR-200, miR-126*, miR-141, miR-29c 
49,21 Dyrskjot, L. et al. Cancer 
research 69, 4851-60 (2009) 
miR-182, miR-183, miR-200a, miR-
143, miR-195 
56 
 miR-145, miR-195, miR-199a*, miR-125b, 
miR-133a, miR-30-a-3p 
49,21 Ichimi, T. et al. International 
journal of cancer. 125, 345-52 
(2009) 
Let7-family (including let-7a), miR-
1268, miR-196a, miR-1, miR-100, 
miR-101, miR-143 
59 
 miR-143 49,21 Noguchi, S. et al. Cancer letters 
307, 211-20 (2011); Noguchi, S. 
et al. Cancer letters 328, 353-61 
(2013); Lin, T. et al. The Journal 
of urology 181, 1372-80 (2009) 
miR-182, miR-183, miR-10a, miR-
203, miR-224, miR-1, miR-143, miR-
145, miR-133a, miR-133b, miR-125b 
57 
 miR-452, miR-452*, miR-7a 49,21 Veerla, S. et al. International 
journal of cancer. 124, 2236-42 
(2009) 
miR-141, miR-200a, miR-200b, miR-
200b*, miR-200c, miR-429, miR-
199a-3p, miR-199a-5p,miR-199b-3p, 
miR-106b, miR-106b*, miR-18a, 
miR-18a*, miR-20a, miR-20a* 
58 
 miR-205 21 Gottardo, F. et al. Urologic 
oncology 25, 387-92 (2007); 
Wiklund, E.D. et al. International 
journal of cancer. 128, 1327-34 
(2011) 
miR-195 and miR-497 60 
 miR-1 21 Yoshino, H. et al. British journal 
of cancer 104, 808-18 (2011) 
miR-99a, miR-100, miR-145, miR-
125b  
61 
 miR-125b 21 Huang, L. et al. International 
journal of cancer 128, 1758-69 
(2011) 
 
 miR-127 21 Saito, Y. et al. Cancer Cell 9, 435-
43 (2006) 
 
 let-7a, miR-30c 21 Wang, G. et al. International 
urology and nephrology 42, 95-
102 (2010) 
 
 miR-10b, miR-29b, miR-142-5p, miR-143, 
miR-145, miR-320 
21 Baffa, R. et al. The Journal of 
pathology 219, 214-21 (2009) 
 
 miR-373, miR-99, miR-100, miR-21 21 Catto, J.W. et al. Cancer research 
69, 8472-81 (2009) 
 
 miR-145 21 Ostenfeld, M.S. et al. Oncogene 
29, 1073-84 (2010) 
 
 miR-221 21 Lu, Q. et al. Urologic oncology 
28, 635-41 (2010) 
  
 miR-21, miR-205 21 Neely, L.A. et al. Urologic 
oncology 28, 39-48 (2010) 
 
 miR-221, miR-17-5p, miR-23a, miR-23b, 
miR-26b, miR-103-1, miR-185, miR-203, 
miR-205, miR-223 
21 Gottardo, F. et al. Urologic 
oncology 25, 387-92 (2007)  
 miR-145, miR-101, miR-1, miR-29c, miR-
127, miR-143, miR-182, miR-183,miR-224 
21 Friedman, J.M. et al. Cancer 
research 69, 2623-9 (2009) 
 
Serum 22 miRNA s analysed in serum , no 
DEmiRNAs 
63 Scheffer, A.R. et al. World 
journal of urology 32, 353-8 
(2014) 
miR-152, miR-148b-3p, miR-3187-
3p, miR-15b-5p, miR-27a-3p, miR-
30a-5p  
83 
 miR-21  Sanders, I. et al. International 
journal of urology 19, 1017-25 
(2012) 
 
Plasma miR-148b, miR-200b, miR-487, miR-541, 
miR-25, miR-33b, miR-92a, miR-92b, miR-
302  
63,81 82 Not available   
 miR-497, miR-663b  Du, M. et al. Scientific reports 5, 
10437 (2015) 
 
Urine miR-126, miR-152  92, 93, 63 90 Not available   
 miR-143, miR-222, miR-452  92,63 Puerta-Gil, P. et al. The American 
journal of pathology 180, 1808-
15 (2012) 
 
 miR-96, miR-183  92, 93, 63 Yamada, Y. et al. Cancer science 
102, 522-9 (2011) 
 
 miR-200 family, miR-192, miR-155, miR-
146, miR-205  
92, 93, 63 Wang, G. et al. Clinical 
genitourinary cancer 10, 106-13 
(2012) 
 
 miR-145, miR-200a  92, 93, 63 Yun, S.J. et al. International 
journal of oncology 41, 1871-8 
(2012) 
  
 miR-15a, miR-15b, miR-24-1, miR-27b, miR-
100, miR-135b, miR-203, miR-212, miR-328, 
miR-1224  
92,63 Miah, S. et al. British journal of 
cancer 107, 123-8 (2012) 
 
 miR-125b, miR-126  92,63 Snowdon, J., et al. Canadian 
Urological Association journal 1-5 
(2012) 
 
 miR-182, miR-199a, miR-126 21 Hanke, M. et al. Urologic oncology 
28, 655-61 (2010) 
 
 miR-18a*, miR-25, miR-187, miR-140-5p, 63 Mengual, L. et al. International  
miR-142-3p, miR-204, miR-125b,miR-92a journal of cancer. 133, 2631-41 
(2013) 
  miR-520e, miR-618, miR-1225-5p 63 Tolle, A. et al. Oncology reports 30, 
1949-56 (2013) 
  
miRNAs deregulated in more than one study with the same technique are in bold. miRNAs deregulated in more than one study with different techniques are 
underlined 
 
Table 2 MiRNA profiling by NGS as BC biomarker of diagnosis in normal versus cancer tissues  
Reference Tissue 
collection/
storage 
Patients in the 
NGS process 
(Cases/controls) 
Ethnicity Results NGS 
instrument 
Validation Note 
Han et al 
2011 56 
Snap-
frozen 
tissues in 
liquid 
nitrogen 
9 tissues and 9 
NBE (all males) 
Chinese 656 DEmiRNAs. 
miR-96 and miR-
490-5p the most 
significantly up-
regulated and 
down-regulated 
miRNAs, resp. 
 
Illumina 
Genome 
Analyzer IIx 
Yes (qRT-PCR) 
5 miRNAs were 
validated (BC and 
matched NBE) by 
qRT-PCR on tissues 
from 42 BC 
samples. 3 miRNAs 
resulted 
overexpressed 
(miR-182, miR-183, 
and miR200a) and 2 
miRNAs down-
regulated (miR-143 
and miR-195) 
• Mixed 
High/low 
grade and 
mixed I, II 
and IV 
grade 
• 92 novel 
miRNAs 
candidate 
detected 
Chen et al 
2013 59 
Snap-
frozen 
tissues in 
liquid 
20 BC cases 
analyzed in pool 
and 10 NBE in 
pool 
Chinese 74 DEmiRNAs 
among tumors 
and controls (33 
up- and 41 down-
Solexa 
sequencing-
by-synthesis  
No • Mixed I, II 
and III 
grade.  
• Mixed Ta, 
T1, T2 and 
T3 tumor 
nitrogen  regulated)  stage. 
• Mixed 
genders. 
• Identified 
317 and 57 
novel 
miRNAs in 
BC library 
and NBE 
library, 
separately.  
• 13 novel 
miRNAs 
identified in 
both BC 
and NBE 
libraries 
Zhu et al 
2011 57 
Partly same 
data of Han 
et al 2011 56 
RNA later-
preserved 
or snap-
frozen 
tissues in 
liquid 
nitrogen 
9 BC tissues and 9 
NBE (all males) 
Chinese 196 DEmiRNAs 
among BC 
tissues and 
matched normal 
tissues(156 up-
regulated and 40 
down-regulated) 
Illumina 
Genome 
Analyzer IIx 
No • Mixed 
High-/low-
grade T 
ranging 
from T1 to 
T4 
• Results 
were in 
general in 
agreement 
with 
previous 
results in 
BC 
Li et al 2011 
58 
Partly same 
data of Han 
et al 2011 56 
RNA later-
preserved 
or snap-
frozen 
tissues in 
liquid 
nitrogen  
10 BC tissues (all 
males) 
Chinese 226 DEmiRNAs 
(182 up- and 44 
down-regulated) 
in BC 
124 miRNAs with 
significantly 
different 
expression 
uniquely on BC 
and 17 miRNAs 
in common 
among the 3 
cancers 
Illumina 
Genome 
Analyzer IIx 
No • Mixed 
High-/low-
grade T 
ranging 
from T1 to 
T4 
Itesako et al 
2014 60 
Tissue 
samples in 
RNA later 
5 BC tissues and 5 
NBE 
Japanese 60 miRNAs were 
found down-
regulated in BC 
tissues when 
compared with 
NBE 
Illumina 
Genome 
Analyzer IIx 
Yes (qRT-PCR) 
Validation of miR-
195 and miR-497on 
29 BC tissues and 
on 20 NBE  
• Mixed BC 
with no 
specified 
grade, T 
ranging 
from T2 to 
T3 
• Identified 
933 known 
miRNAs 
and 17 
candidate 
new 
miRNAs.  
The Cancer 
Genome 
Atlas 
Research 
Network, 
2014 61 
Snap-
frozen 
tissue 
samples 
131 MIBC tissues, 
23 NBE, 118 
peripheral blood 
(used as surrogate 
normal tissue) 
American 
(USA) 
Not specified 
overall results. 
miR-99a and 
miR-100 were 
found down-
regulated in 
cluster I tissues 
that have also 
down-regulation 
of FGFR3 (known 
target of the cited 
miRNAs) 
miR-145 and 
miR-125b were 
found down-
regulated in the 
same cluster 
Illumina 
HiSeq 
NA  
BC= bladder cancer; NBE=normal bladder epithelium; NA=not applicable; MIBC= muscle-invasive bladder cancer; DEmiRNAs= 
differentially expressed miRNAs 
Table 3 MiRNA profiling by NGS as BC biomarker of diagnosis in biofluids 
Reference Biofluids Patients in the 
NGS process 
(Cases/controls) 
Ethnicity Results NGS 
instrument 
Validation Note 
Jiang et al 
2014 83 
Serum 10 NMIBC cases 
pooled, 10 MIBC 
pooled and 10 
healthy controls  
Chinese 26 DEmiRNAs 
in BC in which 
8 miRNAs 
were up-
regulated and 
18 miRNAs 
were down-
regulated 
Illumina 
Miseq 
Yes (qRT-PCR) 
6 DEmiRNAs (miR-
152, and miR-148b-
3p up-regulated; 
miR-3187-3p, miR-
15b-5p, miR-27a-3p 
and miR-30a-5p 
down-regulated) in 
BC and control group 
both in training set 
(120 BC and 120 
controls) and in the 
validation phase (110 
BC and 110 controls)  
• Mixed High-
/low-grade and 
MIBC and 
NMIBC 
• Mixed genders 
(80% males) 
• miR-152 
identified as an 
independent 
factor for tumor 
recurrence in 
NMIBC 
 
Cheng et 
al 2014 91 
Urine 
(exosomes) 
3 healthy donors Caucasian 
(Australia) 
12 miRNAs 
abundantly 
expressed in 
cell-free urine; 
66-184 
miRNAs 
abundantly 
expressed in 
exosomes 
Life 
technologies 
Ion Torrent 
NA  
BC= bladder cancer; NMIBC=non muscle-invasive bladder cancer ; MIBC= muscle-invasive bladder cancer; NA=not applicable; 
DEmiRNAs= differentially expressed miRNAs  
  
 
Figure 1. Putative sources of circulating microRNAs (miRNA). MiRNAs in circulation may originate from 
apoptotic or necrotic cells as well as cancer cells from advanced/metastatic bladder tumor. MiRNAs may be 
released in blood vessels aggregated to protein complexes or via secretory vesicles such as exosomes or 
microvesicles. In addition, they can also be secreted in free form by some unknown mechanisms. Urinary 
miRNA originates from renal and urethral cells. As plasma/serum circulating extracellular miRNA from other 
tissues within the body can be delivered to renal epithelial cells and released into the urine. In noninvasive BC, 
tumor cells having a turnover release also miRNAs bound to RNA-binding proteins or packaged into 
microvesicles such as exosomes. 
